Azenta, Inc. (AZTA)
NASDAQ:AZTA
Want to see AZTA full AI Analyst Report?
Top Page
Azenta
(NASDAQ:AZTA)
Select Model
Select Model
Rating:54Neutral
Price Target:
$23.50
▼(-16.61% Downside)
Action:Reiterated
Date:05/09/26
AZTA scores mid-range primarily due to a strong balance sheet and improved cash generation alongside renewed TTM revenue growth, but the overall score is held back by persistent losses/negative returns and a cautious outlook after a FY26 guidance reset. Technically, the stock remains in a pronounced downtrend (below key moving averages with negative MACD), reinforcing near-term risk despite oversold readings.
Positive Factors
Strong balance sheet & liquidity
Azenta's sizable cash balance and negligible debt provide durable financial flexibility to fund remediation, modest capex, and M&A without near-term refinancing risk. That conservative capital structure supports multi-quarter execution of turnarounds and investment in product deployment and integration.
Negative Factors
Persistent unprofitability & negative returns
Despite revenue recovery, Azenta still fails to convert sales into profit, producing negative margins and ROE. Persistent losses constrain reinvestment, raise the hurdle for accretive M&A, and imply the company must sustain structural improvements in mix, pricing or cost base to deliver durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet & liquidity
Azenta's sizable cash balance and negligible debt provide durable financial flexibility to fund remediation, modest capex, and M&A without near-term refinancing risk. That conservative capital structure supports multi-quarter execution of turnarounds and investment in product deployment and integration.
Read all positive factors
Azenta Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down sales across regions to show where Azenta earns most of its revenue, revealing exposure to regional biotech demand, regulatory environments, and currency swings. Heavy concentration in a few markets raises risk, while diversified or expanding geography points to broader adoption of its sample-management, cold chain and genomics offerings.
Breaks down sales across regions to show where Azenta earns most of its revenue, revealing exposure to regional biotech demand, regulatory environments, and currency swings. Heavy concentration in a few markets raises risk, while diversified or expanding geography points to broader adoption of its sample-management, cold chain and genomics offerings.
Data provided by:
The Fly
The FlyAzenta (AZTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)965.29K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-5.87%
EPS Growth-175.46%
CountryUS
Employees3,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-3.95
Shares Outstanding46,092,804
10 Day Avg. Volume770,217
30 Day Avg. Volume965,289
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.76
Price to Sales (P/S)2.21
P/FCF Ratio34.28
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit3.30
Enterprise Value/Ebitda17.82
Forecast
1Y Price Target
$30.75Price Target Upside9.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.52
Revenue Forecast (FY)$603.85M
Azenta Business Overview & Revenue Model
Company Description
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences...
How the Company Makes Money
Azenta makes money primarily by selling life-sciences products and services used to store, manage, process, and analyze biological samples. A key revenue stream comes from its Sample Management Solutions activities, which include (1) selling autom...
Azenta Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The call was mixed. Positive operational and recurring-revenue trends (strong biorepository growth, improved on-time delivery, faster RNA-Seq turnaround, solid cash position, and targeted cost savings) coexist with significant near-term challenges: organic revenue decline, notable margin compression, large goodwill impairments (~$149M), automated storage quality remediation and delayed large-capex orders, and a guidance reset lowering FY26 growth and profitability expectations. Management reiterated long-term conviction in strategic priorities and outlined actions (leadership changes, ABS deployment, cost reductions, M&A integration) to address execution gaps, but near-term results and uncertainty weighed on the quarter.Positive Updates
Recurring Revenue Strength — Biorepositories and Services
Sample repository/biorepository solutions (≈40% of SMS) delivered high single-digit growth and supported steady growth in product services, consumables and instruments, reinforcing a durable recurring revenue base that helped partially offset capital equipment softness.
Negative Updates
Organic Revenue Decline and Segment Divergence
Total reported Q2 revenue $145 million (up 1% reported) but down 3% organically (ex-UKBC and FX). Multiomics revenue $64M (flat reported, down ~2% organic) and SMS $81M (up 2% reported, down ~3% organic), reflecting softer demand for capital-intensive products and North America weakness.
Read all updates
Q2-2026 Updates
Positive
Negative
Recurring Revenue Strength — Biorepositories and Services
Sample repository/biorepository solutions (≈40% of SMS) delivered high single-digit growth and supported steady growth in product services, consumables and instruments, reinforcing a durable recurring revenue base that helped partially offset capital equipment softness.
Read all positive updates
Company Guidance
Azenta updated fiscal 2026 guidance to reported revenue of approximately $603 million to $621 million (including UK Biocentre) and organic revenue of down ~2% to up 1% year‑over‑year, with adjusted EBITDA margin expected to be down ~125 basis points to flat versus prior year; free cash flow is now expected to improve ~10%–15% year‑over‑year (vs prior ~30% expectation). For cadence the company expects Q3 organic revenue to grow low single digits and Q4 organic revenue to decline low single digits (Q4 2025 was a tough comp), while adjusted EBITDA margins should improve sequentially into the low‑double‑digit range in Q3 and step up further in Q4. Recent Q2 results underpinning the reset were: revenue $145 million (reported +1%, organic -3%), gross margin 44.3% (down 110 bps), adjusted EBITDA $7.8 million (5.4% of revenue, down 320 bps), non‑GAAP EPS loss $0.04, free cash flow (including B Medical) $5 million, cash and equivalents $565 million, capex ~$7 million, and Q2 charges including $112.4 million and $36.6 million goodwill impairments (Multiomics and SMS), a $6 million noncash loss on assets held for sale, ~ $2 million of store rework quality costs, and an expected completion of remaining store remediation by end of Q3; management also pushed the long‑range plan out one year to 2029 while keeping targets unchanged.Azenta Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 596.57M | 593.82M | 573.45M | 665.07M | 555.50M | 513.70M |
| Gross Profit | 265.77M | 270.28M | 254.62M | 233.26M | 230.62M | 214.51M |
| EBITDA | 49.17M | 54.07M | 71.62M | 55.15M | 48.35M | 9.94M |
| Net Income | -178.16M | -55.76M | -164.90M | -14.26M | -428.96M | 110.75M |
Balance Sheet | ||||||
| Total Assets | 1.90B | 2.06B | 2.10B | 2.89B | 3.72B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 380.52M | 340.92M | 462.09M | 1.02B | 1.57B | 227.51M |
| Total Debt | 55.71M | 111.17M | 70.68M | 60.44M | 49.23M | 94.77M |
| Total Liabilities | 349.21M | 330.70M | 331.07M | 351.22M | 352.74M | 494.18M |
| Stockholders Equity | 1.55B | 1.73B | 1.77B | 2.53B | 3.36B | 1.33B |
Cash Flow | ||||||
| Free Cash Flow | 28.72M | 38.32M | 12.35M | -33.60M | -543.48M | 97.05M |
| Operating Cash Flow | 61.01M | 72.18M | 49.74M | 5.83M | -466.05M | 149.86M |
| Investing Cash Flow | -105.52M | -90.46M | 224.74M | 431.38M | 1.47B | -146.35M |
| Financing Cash Flow | -963.00K | -9.59M | -659.21M | -840.46M | -62.76M | -25.91M |
Azenta Technical Analysis
Neutral
28.18
Price Trends
21.72
Positive
26.52
Negative
29.19
Negative
Market Momentum
-0.33
Negative
59.62
Neutral
94.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Neutral. The current price of 28.18 is above the 20-day moving average (MA) of 19.74, above the 50-day MA of 21.72, and below the 200-day MA of 29.19, indicating a neutral trend. The MACD of -0.33 indicates Negative momentum. The RSI at 59.62 is Neutral, neither overbought nor oversold. The STOCH value of 94.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AZTA.
Azenta Risk Analysis
Azenta disclosed 35 risk factors in its most recent earnings report. Azenta reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Azenta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.40B | -291.18 | -0.95% | ― | 15.01% | 88.10% | |
65 Neutral | $1.22B | -115.05 | -2.91% | ― | -5.48% | -666.94% | |
58 Neutral | $1.49B | -70.93 | -6.07% | ― | 4.03% | 70.55% | |
55 Neutral | $208.85M | -5.91 | -246.44% | ― | 17.41% | -189.91% | |
54 Neutral | $1.05B | -5.92 | -10.69% | ― | -5.87% | -175.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $887.85M | -0.73 | -56.31% | ― | -3.87% | -258.96% |
* Healthcare Sector Average
AZTA
Azenta
22.88
-3.75
-14.08%
ATRC
Atricure
27.67
-6.33
-18.62%
QDEL
QuidelOrtho
13.02
-16.63
-56.09%
STAA
Staar Surgical
29.89
13.20
79.09%
BLFS
BioLife Solutions
24.92
4.23
20.44%
SMTI
Sanara MedTech
22.79
-6.30
-21.66%
Azenta Corporate Events
Business Operations and StrategyExecutive/Board Changes
Azenta Reshapes Multiomics Leadership and Executive Compensation
Positive
Apr 7, 2026
On April 6, 2026, Azenta implemented a leadership change in its Multiomics business, with Ginger Zhou stepping down as president and continuing as an adviser through November 2026 under a consulting agreement, while William “Trey” E. M...
Business Operations and StrategyM&A Transactions
Azenta Faces Delay in B Medical Systems Divestiture
Negative
Apr 2, 2026
Azenta, Inc. disclosed that a planned sale of the entire issued share capital of its subsidiary B Medical Systems S.À R.L. to Thelema S.À R.L., initially expected to close on or before March 31, 2026, did not close as scheduled because T...
Business Operations and StrategyM&A Transactions
Azenta Acquires UK Biocentre to Expand European Biorepository
Positive
Mar 4, 2026
On March 4, 2026, Azenta announced that its subsidiary Azenta UK Ltd had completed the acquisition of UK Biocentre Limited, a UK-based provider of sample management, storage and high-throughput processing services, for total consideration of GBP 2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.